Resources

A new white paper from Pharmaceutical Technical Solutions, Inc. (PTSI) reveals how leading biomanufacturers are reducing CapEx and accelerating timelines by rethinking facility design. Learn how eliminating in-house high-purity water systems and buffer/media prep suites can maximize return on invested capital (ROIC) and streamline your path to production. Backed by real-world data and facility design expertise, this is essential insight for your next build.

This white paper provides actionable guidance for cell therapy developers navigating the complex decisions around human AB serum selection, regulatory compliance, and supply chain risk management. Download the full document to access detailed regulatory frameworks, supplier qualification criteria, and strategic decision trees.